Stock RASP ACTAVIA LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Actavia Life Sciences, Inc.

Equities

RASP

US7538881068

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 12:28:19 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.0173 USD +121.79% Intraday chart for Actavia Life Sciences, Inc. +121.79% +124.68%
Feb. 16 Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Jan. 05 Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI

Valuation

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Capitalization 1 33.08 10.34 5.168 4.134 2.196 15.44
Enterprise Value (EV) 1 33.17 10.55 5.676 4.716 2.376 15.57
P/E ratio -8.11 x -11 x -0.97 x -5.27 x -1.98 x -2 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -8.16 x -11.6 x -10.2 x -19.1 x -6.19 x -
EV / FCF -30.1 x 45 x -29.5 x 184 x -4.6 x 9.9 x
FCF Yield -3.32% 2.22% -3.39% 0.54% -21.7% 10.1%
Price to Book 10.7 x 4.07 x -1.93 x -1.55 x -1.3 x -7.89 x
Nbr of stocks (in thousands) 68,908 68,908 68,908 68,908 179,979 771,811
Reference price 2 0.4800 0.1500 0.0750 0.0600 0.0122 0.0200
Announcement Date 12/24/18 1/13/20 1/15/21 3/1/22 2/9/23 1/5/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -4.065 -0.9117 -0.5549 -0.2475 -0.3836 -
EBIT 1 -4.07 -0.9152 -0.5565 -0.2478 -0.3839 -4.238
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -4.074 -0.944 -5.35 -0.7851 -0.6866 -4.443
Net income 1 -4.076 -0.9364 -5.347 -0.7851 -0.6866 -4.443
Net margin - - - - - -
EPS 2 -0.0592 -0.0136 -0.0776 -0.0114 -0.006161 -0.0100
Free Cash Flow 1 -1.103 0.2346 -0.1922 0.0256 -0.5164 1.573
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/24/18 1/13/20 1/15/21 3/1/22 2/9/23 1/5/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022 2023
Net Debt 1 0.09 0.21 0.51 0.58 0.18 0.14
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.0233 x -0.2356 x -0.9148 x -2.348 x -0.4701 x -
Free Cash Flow 1 -1.1 0.23 -0.19 0.03 -0.52 1.57
ROE (net income / shareholders' equity) -89.2% -33.2% 7,786% 29.4% 30.9% 244%
ROA (Net income/ Total Assets) -39.7% -11.2% -14% -400% -370% -2,928%
Assets 1 10.26 8.326 38.27 0.1965 0.1858 0.1517
Book Value Per Share 2 0.0500 0.0400 -0.0400 -0.0400 -0.0100 -0
Cash Flow per Share 2 0 0 0 0 0 0
Capex 1 0 - - - - -
Capex / Sales - - - - - -
Announcement Date 12/24/18 1/13/20 1/15/21 3/1/22 2/9/23 1/5/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTAVIA LIFE SCIENCES, INC. Stock Actavia Life Sciences, Inc.
+124.68% 13.35M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.15% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.60% 101B
ARGENX SE Stock argenx SE
+4.40% 23.07B
BIONTECH SE Stock BioNTech SE
-12.36% 22.23B
GENMAB A/S Stock Genmab A/S
-4.36% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.28% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.75% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.86% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RASP Stock
  4. Financials Actavia Life Sciences, Inc.